Oprah Winfrey says she stopped a GLP-1 for 12 months, then restarted
A celebrity account of stopping a GLP-1 and restarting puts public attention on a common patient question that the interview itself does not answer with clinical detail [1].
Oprah Winfrey said she stopped taking a GLP-1 medication for about twelve months and then started again, describing what happened during the pause in an interview with People published in December 2025 [1]. Her account is one person's experience, not a clinical trial, so it does not show what these drugs do or do not do in general [1].
The interview drew wide attention in part because Winfrey had already spoken publicly about using a GLP-1 medication [1]. In the account, she described the period after she stopped and before she resumed [1].
Several basics were not disclosed. The account does not identify which GLP-1 she took, what dose she was on, how much her weight changed while she was off the medication, or what side effects she had, if any; those details have not been reported [1]. It also has not been reported whether a clinician advised the pause or the restart, what her reasons for stopping were, or how long after resuming the account was given [1].
Because the account is a single case, it cannot establish how common it is for people to stop a GLP-1 and later start again. No figures on how many patients pause and restart, or on how their outcomes compare with people who stay on treatment, are included in the account [1].
Why it matters for patients
For people taking or considering a GLP-1, the interview puts a practical question in public view: what happens when the medication stops? The account describes one person's experience but does not supply the kind of information that would apply to anyone else. It does not say how quickly appetite or weight changed after she stopped, whether side effects returned when she restarted, or how the gap affected cost or insurance coverage [1]. Those details have not been reported [1].
Patients and prescribers commonly discuss questions like these when someone is thinking about a break in treatment. The account does not describe what medical guidance she received, if any, or whether the stop and restart were planned [1]. It also does not address whether the drug she used was approved for weight management, for type 2 diabetes, or for another use, because the medication itself has not been identified [1].
It is worth separating what the interview does and does not show. A single, widely covered anecdote can tell readers that stopping and restarting happens, but it cannot say how often, for whom, or with what results. Those answers would come from studies or from real-world data, and no such figures are part of this account [1].
What happens next
No follow-up interview, statement or additional clinical detail has been reported since the People interview [1]. No dates for any further public update have been given, and no medical information beyond what was described in that interview has been disclosed [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.